The good news is that the team at UBS don’t believe that Vyvgart will have an overly large impact on CSL’s revenue. It sees the worst-case scenario as a ~3% revenue hit. Though, even then, the broker feels that is unlikely.As a result, it may be unnecessary to worry too much about this news. And with UBS retaining its buy rating and $340.00 price target, it could prove to be an opportune time to pick up CSL shares while they are cheap.
UBS - CSL no need to worry about Argenx
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$288.79 |
Change
-0.140(0.05%) |
Mkt cap ! $139.8B | |||
| Open | High | Low | Value | Volume |
| $289.90 | $290.00 | $287.43 | $81.59M | 282.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1859 | $288.71 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $288.79 | 8 | 1 |
View Market Depth
| Last trade - 16.10pm 07/10/2024 (20 minute delay) ? |
| CSL (ASX) Chart |